Recombinant Protein Expression & Co-Development Partnership

KAICO, a biotech startup from Kyushu University (Japan), specializes in recombinant protein production using its proprietary silkworm–baculovirus expression system. This unique platform achieves a 100% success rate in protein expression, enabling efficient and scalable production of proteins that are often difficult to obtain with conventional systems.

Our technology is already delivering impact:

• Commercialized Product: We launched an immune-enhancing feed additive for pigs, now marketed in Vietnam under the feed additive category.

• Human Vaccine Development: We are preparing to enter Clinical Phase I trials in 2026 for a human norovirus vaccine, supported by Japan’s AMED/SCARDA program.

We seek collaboration with pharmaceutical and biotechnology companies interested in:

• Development of recombinant proteins for APIs, reagents, and antigens

• Support in vaccine and therapeutic protein development

• Co-development projects leveraging our protein expression expertise

By combining KAICO’s proven expression system with partner pipelines, we can accelerate innovation and bring next-generation pharmaceuticals to market.